Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 5Multiple Myeloma 4Melanoma 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Solid Tumors 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immune-related Adverse Events 1Hematologic Neoplasms 1Glioblastoma 1Craniopharyngioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Basal Cell 1Breast Neoplasms 1Bone Neoplasms 1Astrocytoma 1

Interventions

Rituximab 23Cyclophosphamide 15ibrutinib 14acalabrutinib 13CT-P10 10venetoclax 8Lenalidomide 8Bendamustine Hydrochloride 8fludarabine 7Cytarabine 6fludarabine phosphate 5zanubrutinib 4obinutuzumab 4Peripheral Blood Stem Cell Transplantation 4Methotrexate 4pirtobrutinib 3Whole-Body Irradiation 3Tacrolimus 3Mycophenolic Acid 3Melphalan 3Etoposide 3palbociclib 2merphos 2dexamethasone acetate 2dexamethasone 21-phosphate 2brexucabtagene autoleucel 2auricularum 2Vincristine 2Stem Cell Transplantation 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Mantle-Cell × tocilizumab × Clear all
NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
24 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡